California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Sutter Auburn Faith Hospital, Auburn, California
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Kaiser Permanente-Anaheim, Anaheim, California
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
NCT05514899
Recruiting
This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures d... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
02/14/2025
Locations: HIV Neurobehavioral Research Program (HNRP), San Diego, California
Conditions: Hiv, Cannabis, THC, Neuroinflammatory Disease, Neuroinflammatory Response, Microbiome
Register for Updates
Transcutaneous Spinal Cord Stimulation for Chronic Low Back Pain
NCT05265000
Recruiting
As a leading cause of disability worldwide, chronic low back pain (cLBP) represents a significant medical and socioeconomic problem with estimated health care spending of $87 billion/annually. The efficacy of dorsal column electrical stimulation to inhibit pain was first described over 50 years ago. Since then, several large clinical trials have investigated the therapeutic potential of electrical spinal cord stimulation (SCS) and found that over 70% of patients with intractable pain had over 50... Read More
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
02/14/2025
Locations: San Francisco VA Medical Center, San Francisco, California
Conditions: Chronic Low-back Pain
Register for Updates
Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy
NCT03487185
Recruiting
A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Regents of the University of California San Francisco, San Francisco, California
Conditions: Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
Register for Updates
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT03384238
Recruiting
This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/14/2025
Locations: Stanford University, School of Medicine, Palo Alto, California
Conditions: Pancreatic Adenocarcinoma
Register for Updates
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
NCT02923011
Recruiting
Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of osteoid osteomas, and offers possible improvements with regards to 1) post-procedural pain, 2) clinical resource utilization, 3) patient experience, and/or 4) adverse events. The data from the current... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
02/14/2025
Locations: Stanford Medical Center, Palo Alto, California
Conditions: Osteoid Osteoma
Register for Updates
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299
Recruiting
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Genesis Research, LLC, San Diego, California
Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Register for Updates
Advance Care Planning With Formerly Homeless Older Adults Residing in Permanent Supportive Housing
NCT06239896
Recruiting
The homeless population is aging, with an increasing proportion of individuals over age 50 who experience accelerated aging, high rates of mortality, and a high risk of not having their wishes honored at the end of life. The goal of this randomized control trial (RCT) is to test the effectiveness of adapted evidence-based advance care planning (ACP) interventions for formerly chronically homeless older adults living in permanent supportive housing (PSH).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/13/2025
Locations: Abode Services, Fremont, California
Conditions: Advance Care Planning
Register for Updates
MCT for the Harvard/UCSF ROBIN Center
NCT06000787
Recruiting
The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that underlie how radiation treats tumors but also can cause unwanted side effects. The MCT focuses on collection of research biospecimens before, during, and after radiation. Also critical to the MCT is the de... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/13/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Glioma, Childhood Brainstem, Neuroblastoma
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Chula Vista, California
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
NCT05695027
Recruiting
The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
02/13/2025
Locations: Stanford University Department of Ophthalmology, Palo Alto, California
Conditions: Primary Open Angle Glaucoma
Register for Updates